Updated Guidance Suggests that Federal Government May Enforce Contractor Vaccine Mandate
Client Alert | 1 min read | 10.18.22
The Safer Federal Workforce Task Force issued updated guidance for federal contractors on October 14, 2022, announcing that it will reevaluate enforcement of the federal contractor vaccine mandate and safety requirements issued under Executive Order 14042. This is the first pronouncement from the Task Force after it had indicated that it would not enforce the vaccine mandate without further notice in the wake of the Eleventh Circuit’s August 26, 2022 decision limiting the scope of the injunction against implementation and enforcement of the EO 14042 contractor mandate. The mandate officially narrowing the injunction was issued on October 18.
In light of the narrowed injunction, the Task Force announced that it will not enforce the vaccine mandate unless and until (i) the Task Force issues new guidance on COVID-19 safety protocols, (ii) OMB determines that guidance would promote economic and efficiency in federal contracting, and (iii) agencies issue written notice to covered contractors in accordance with OMB guidelines. The Task Force update leaves open the possibility that agencies could include the FAR clause implementing the requirements of the Executive Order in future solicitations and contracts.
In light of this announcement, federal contractors should expect that the Federal Government will not take any action to enforce the clause implementing the EO 14042 contractor mandate where it has already been included in contracts or contract-like instruments, absent further written notice from the agency.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection




